Selank Benefits: The Claims, Against the Numbers

The compound is a synthetic heptapeptide derived from the endogenous peptide tuftsin, developed in Russia and studied mainly as an anxiolytic. The claims that circulate cluster around anxiety, stress, sleep, attention and mood.

Anxiolytic effects are the claim with the most behind it, because that is what the Russian clinical literature in humans examined and it is the indication the compound is registered for in that country. Claims about attention, memory or nootropic effect drift outward from there with progressively less support, and by the time a benefits list reaches broad cognitive enhancement it is quoting an extrapolation rather than a result.

None of it has been examined in a registered Western trial. There is no such trial to cite, so no trial identifier appears on this page, and any article that offers one for this compound has either matched a text search or invented it.

The bottom row is the one that gets skipped. A vial or spray bought from a research chemical vendor is not the registered Russian product, whatever the molecule inside is meant to be. Registration attaches to a manufactured medicine, with an enforced production standard and a reviewed label. It does not travel with the name.

The drift from a narrow finding to a broad benefit follows a predictable path, and it is worth being able to name the steps.

It starts with an indication: an anxiolytic effect examined in humans within one country's clinical system. The first widening drops the population, so a finding in a defined clinical group becomes a statement about people in general. The second drops the outcome, so a rating scale for anxiety becomes calm, focus and resilience, which are three different things and none of them is the thing that was measured.

The third widening borrows from the animal work. Mechanistic findings in rats and mice are genuine results about rodents, and they get quoted as if they described what a person would notice. The fourth drops the format, so a claim derived from one preparation is repeated for a differently prepared vial or spray without the concentration ever being mentioned.

By the end of that chain a product page is describing general cognitive enhancement, and every qualifier that made the original finding meaningful has been shed. Nothing in the chain requires anyone to lie. Each step is a small compression of the sentence before it, which is why the drift is so hard to spot from the finished text alone. Working backwards to ask which organism, which outcome and which preparation is the only reliable way to unwind it.

A claimed benefit attaches to an amount, and an amount only exists once a container has been prepared. This compound is sold in two formats and they reach a mass by different routes.

For a vial of powder, concentration is labelled mass divided by the volume of bacteriostatic water added. A 5 mg vial with 2.5 mL gives 5 divided by 2.5, which is 2 mg per mL. On a U-100 syringe, which fills 1 mL at 100 units so that one unit is 0.01 mL, ten units are 0.1 mL and hold 2 times 0.1, which is 0.2 mg, or 200 mcg.

For a nasal spray, concentration is the labelled mass divided by the fill volume, and the delivered amount is that concentration multiplied by the volume the pump releases per actuation. A 5 mg bottle filled to 2.5 mL is also 2 mg per mL. With a pump the manufacturer states delivers 0.1 mL, one actuation carries 2 times 0.1, which is 0.2 mg, or 200 mcg. With a pump delivering 0.05 mL, the same bottle gives 100 mcg per actuation.

The two formats can therefore match exactly, or differ by a factor of two, using identical labels. What decides it is the pair of numbers nobody writes down: the liquid volume and the delivered volume.

Yield is mass divided by the mass per event. The 5 mg vial above, drawn 200 mcg at a time, gives 5 divided by 0.2, which is 25 withdrawals. The 2.5 mL spray bottle at 0.1 mL per actuation gives 2.5 divided by 0.1, which is 25 actuations, before priming and residual volume are subtracted. Priming a new pump consumes several strokes and the dip tube leaves liquid behind, so the practical count is lower and the label does not say by how much.

Cost per mg is price divided by labelled mass, and it is the only comparison that survives across formats. On assumed figures, since no seller is named here, a 5 mg vial at 45 currency units is 9 per mg and a pre-filled 5 mg spray at 60 is 12 per mg. Cost per event divides again: 45 divided by 25 is 1.80 for the vial, and 60 divided by 25 is 2.40 for the spray, before the priming loss makes the second figure worse.

That arithmetic is exact and it is blind to everything that matters most. It divides by a labelled mass, which is a seller's claim rather than an assay, so a vendor who overstates the label wins on this metric without shipping anything.

For a compound with a real clinical history in one country, the gap is unusually sharp. There is no Western trial, no Western authorisation, no independent replication of the Russian work in the other system, and no assay of any given vial unless the buyer commissions one.

What exists is a registered medicine in one jurisdiction, a body of clinical work in humans behind it, animal work in rats and mice, and a research chemical market selling material under the same name with none of the accompanying guarantees. A benefits list that mentions only the first part is advertising. One that mentions only the last part is wrong about the literature. The honest version keeps both in view and stops well short of telling anyone what to take.